Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Emerald Health Therapeutics, Inc. stock logo
EMH
Emerald Health Therapeutics
C$0.26
-3.8%
C$0.26
C$0.15
C$0.53
C$52.28MN/A644,760 shs384,329 shs
Hemostemix Inc. stock logo
HEM
Hemostemix
C$0.14
-6.9%
C$0.12
C$0.04
C$0.43
C$19.67M0.2409,782 shs313,700 shs
BeOne Medicines Ltd. - Sponsored ADR stock logo
ONC
BeOne Medicines
$244.47
+1.4%
$247.43
$143.00
$287.88
$26.41B0.28331,684 shs265,156 shs
Promis Neurosciences stock logo
PMN
Promis Neurosciences
$0.40
-1.1%
$0.51
$0.38
$2.37
$13.36M-0.182,328 shs232,557 shs
7 Energy Stocks to Buy and Hold Forever Cover

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Emerald Health Therapeutics, Inc. stock logo
EMH
Emerald Health Therapeutics
0.00%0.00%0.00%0.00%0.00%
Hemostemix Inc. stock logo
HEM
Hemostemix
-6.90%+3.85%+17.39%+42.11%+200.00%
BeOne Medicines Ltd. - Sponsored ADR stock logo
ONC
BeOne Medicines
+1.44%-0.28%-4.45%+18.49%+24,446,999,900.00%
Promis Neurosciences stock logo
PMN
Promis Neurosciences
-4.19%-17.32%-15.42%-28.61%-79.68%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Emerald Health Therapeutics, Inc. stock logo
EMH
Emerald Health Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
Hemostemix Inc. stock logo
HEM
Hemostemix
N/AN/AN/AN/AN/AN/AN/AN/A
BeOne Medicines Ltd. - Sponsored ADR stock logo
ONC
BeOne Medicines
3.3751 of 5 stars
4.50.00.00.02.51.70.6
Promis Neurosciences stock logo
PMN
Promis Neurosciences
3.3559 of 5 stars
3.55.00.00.00.00.81.3
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Emerald Health Therapeutics, Inc. stock logo
EMH
Emerald Health Therapeutics
0.00
N/AN/AN/A
Hemostemix Inc. stock logo
HEM
Hemostemix
0.00
N/AN/AN/A
BeOne Medicines Ltd. - Sponsored ADR stock logo
ONC
BeOne Medicines
3.00
Buy$320.6731.17% Upside
Promis Neurosciences stock logo
PMN
Promis Neurosciences
3.00
Buy$4.501,013.03% Upside

Current Analyst Ratings Breakdown

Latest HEM, ONC, EMH, and PMN Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/27/2025
BeOne Medicines Ltd. - Sponsored ADR stock logo
ONC
BeOne Medicines
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$313.00 ➝ $330.00
6/27/2025
BeOne Medicines Ltd. - Sponsored ADR stock logo
ONC
BeOne Medicines
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$317.00 ➝ $321.00
6/27/2025
BeOne Medicines Ltd. - Sponsored ADR stock logo
ONC
BeOne Medicines
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeOutperform ➝ Moderate Buy$311.00
5/12/2025
Promis Neurosciences stock logo
PMN
Promis Neurosciences
Maxim Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$3.00
5/8/2025
BeOne Medicines Ltd. - Sponsored ADR stock logo
ONC
BeOne Medicines
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$312.00 ➝ $311.00
5/8/2025
BeOne Medicines Ltd. - Sponsored ADR stock logo
ONC
BeOne Medicines
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$348.00 ➝ $350.00
4/28/2025
BeOne Medicines Ltd. - Sponsored ADR stock logo
ONC
BeOne Medicines
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform$312.00 ➝ $312.00
4/24/2025
BeOne Medicines Ltd. - Sponsored ADR stock logo
ONC
BeOne Medicines
TD Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$334.00 ➝ $334.00
4/21/2025
BeOne Medicines Ltd. - Sponsored ADR stock logo
ONC
BeOne Medicines
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$311.00 ➝ $317.00
4/16/2025
BeOne Medicines Ltd. - Sponsored ADR stock logo
ONC
BeOne Medicines
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy
4/10/2025
BeOne Medicines Ltd. - Sponsored ADR stock logo
ONC
BeOne Medicines
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$348.00 ➝ $348.00
(Data available from 7/9/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Emerald Health Therapeutics, Inc. stock logo
EMH
Emerald Health Therapeutics
C$13.02M4.02C$0.33 per share0.78C$0.40 per share0.64
Hemostemix Inc. stock logo
HEM
Hemostemix
N/AN/AC$0.01 per share10.77C($0.10) per shareN/A
BeOne Medicines Ltd. - Sponsored ADR stock logo
ONC
BeOne Medicines
$3.81B7.03N/AN/A$34.10 per share7.17
Promis Neurosciences stock logo
PMN
Promis Neurosciences
N/AN/AN/AN/A$0.50 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Emerald Health Therapeutics, Inc. stock logo
EMH
Emerald Health Therapeutics
N/A-C$0.70N/AN/AN/AN/AN/AN/A
Hemostemix Inc. stock logo
HEM
Hemostemix
-C$5.00M-C$0.03N/AN/AN/A37.07%-349.24%N/A
BeOne Medicines Ltd. - Sponsored ADR stock logo
ONC
BeOne Medicines
-$644.79M-$3.72N/A344.32N/A-9.40%-7.55%-4.42%N/A
Promis Neurosciences stock logo
PMN
Promis Neurosciences
$2.78M-$0.05N/AN/AN/AN/A-186.19%-98.56%8/6/2025 (Estimated)

Latest HEM, ONC, EMH, and PMN Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/12/2025Q1 2025
Promis Neurosciences stock logo
PMN
Promis Neurosciences
-$0.14-$0.21-$0.07-$0.21N/AN/A
5/7/2025Q1 2025
BeOne Medicines Ltd. - Sponsored ADR stock logo
ONC
BeOne Medicines
-$0.71$1.22+$1.93$0.01$1.12 billion$1.12 billion
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Emerald Health Therapeutics, Inc. stock logo
EMH
Emerald Health Therapeutics
N/AN/AN/AN/AN/A
Hemostemix Inc. stock logo
HEM
Hemostemix
N/AN/AN/AN/AN/A
BeOne Medicines Ltd. - Sponsored ADR stock logo
ONC
BeOne Medicines
N/AN/AN/AN/AN/A
Promis Neurosciences stock logo
PMN
Promis Neurosciences
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Emerald Health Therapeutics, Inc. stock logo
EMH
Emerald Health Therapeutics
35.45
2.97
2.61
Hemostemix Inc. stock logo
HEM
Hemostemix
-55.07
0.04
0.48
BeOne Medicines Ltd. - Sponsored ADR stock logo
ONC
BeOne Medicines
0.05
1.96
1.71
Promis Neurosciences stock logo
PMN
Promis Neurosciences
N/A
3.36
3.36

Institutional Ownership

CompanyInstitutional Ownership
Emerald Health Therapeutics, Inc. stock logo
EMH
Emerald Health Therapeutics
N/A
Hemostemix Inc. stock logo
HEM
Hemostemix
N/A
BeOne Medicines Ltd. - Sponsored ADR stock logo
ONC
BeOne Medicines
48.55%
Promis Neurosciences stock logo
PMN
Promis Neurosciences
50.13%

Insider Ownership

CompanyInsider Ownership
Emerald Health Therapeutics, Inc. stock logo
EMH
Emerald Health Therapeutics
N/A
Hemostemix Inc. stock logo
HEM
Hemostemix
10.43%
BeOne Medicines Ltd. - Sponsored ADR stock logo
ONC
BeOne Medicines
6.62%
Promis Neurosciences stock logo
PMN
Promis Neurosciences
6.11%
CompanyEmployeesShares OutstandingFree FloatOptionable
Emerald Health Therapeutics, Inc. stock logo
EMH
Emerald Health Therapeutics
161205.03 millionN/ANot Optionable
Hemostemix Inc. stock logo
HEM
Hemostemix
N/A145.73 millionN/ANot Optionable
BeOne Medicines Ltd. - Sponsored ADR stock logo
ONC
BeOne Medicines
11,000109.60 million102.34 millionN/A
Promis Neurosciences stock logo
PMN
Promis Neurosciences
532.69 million30.69 millionNot Optionable

Recent News About These Companies

ProMIS Neurosciences reports FY24 EPS 11c vs. ($1.07) last year
ProMIS Neurosciences doses first patiets in Phase 1b PRECISE-AD trial
ProMIS Neurosciences seperates from COO Malenfant, terminates COO position
ProMIS Neurosciences anticipates PRECISE-AD interim patient data in 1H26

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Emerald Health Therapeutics stock logo

Emerald Health Therapeutics CVE:EMH

C$0.26 -0.01 (-3.77%)
As of 04/26/2021

Emerald Health Therapeutics, Inc., together with its subsidiaries, produces and sells medical cannabis for medical purpose in Canada. The company is also involved in developing natural health products. It offers dried cannabis strains, pre-rolls, and cannabis oil products to its medical patients. The company was formerly known as T-Bird Pharma Inc. and changed its name to Emerald Health Therapeutics, Inc. in June 2015. Emerald Health Therapeutics, Inc. is headquartered in Vancouver, Canada.

Hemostemix stock logo

Hemostemix CVE:HEM

C$0.14 -0.01 (-6.90%)
As of 07/8/2025 12:16 PM Eastern

Hemostemix Inc., a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia. The company also develops NCP-01, which is preclinical trial to evaluate effect on neuropathic pain and motor function recovery. Hemostemix Inc. is headquartered in Calgary, Canada.

BeOne Medicines stock logo

BeOne Medicines NASDAQ:ONC

$244.47 +3.48 (+1.44%)
As of 07/8/2025 04:00 PM Eastern

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.

Promis Neurosciences stock logo

Promis Neurosciences NASDAQ:PMN

$0.40 0.00 (-1.05%)
Closing price 07/8/2025 03:57 PM Eastern
Extended Trading
$0.41 +0.01 (+1.41%)
As of 04:24 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

ProMIS Neurosciences, Inc. discovers and develops antibody therapies and therapeutic vaccines neurodegenerative diseases and other misfolded protein diseases in Canada. The company's proprietary discovery platform comprises ProMIS and Collective Coordinates algorithms to predict novel targets known as disease specific epitopes on the molecular surface of misfolded proteins. Its lead product candidates comprise of PMN310, a monoclonal antibody (mAb) for toxic oligomers in AD; PMN267, a TDP-43; and PMN442, a mAb targeting toxic a-syn oligomers and seeding fibrils. The company was formerly known as Amorfix Life Sciences Ltd. and changed its name to ProMIS Neurosciences, Inc. in July 2015. ProMIS Neurosciences, Inc. was incorporated in 2004 and is headquartered in Toronto, Canada.